<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39372967</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2515-1355</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Therapeutic advances in vaccines and immunotherapy</Title><ISOAbbreviation>Ther Adv Vaccines Immunother</ISOAbbreviation></Journal><ArticleTitle>Relative effectiveness of COVID-19 vaccine booster doses in people aged 65 and older-a retrospective cohort study in Türkiye.</ArticleTitle><Pagination><StartPage>25151355241285375</StartPage><MedlinePgn>25151355241285375</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25151355241285375</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/25151355241285375</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Immunization in the elderly population is critical due to the high frequency of health outcomes related to COVID-19.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">This study aimed to compare the effectiveness levels of COVID-19 vaccine schedules in preventing SARS-CoV-2 infection in the older adult group who received at least one booster dose.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Retrospective cohort study.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This study evaluated 8969 adults aged 65 and over in the Sultanbeyli district of İstanbul. COVID-19 vaccination and SARS-CoV-2 polymerase chain reaction testing data between January 14, 2021 and December 2, 2022 were obtained from the National Public Health Management System.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The median age of participants was 71 years. The vaccines were mostly administered as CoronaVac for the first and second doses (81.4% and 82.2%, respectively) and BNT162b2 for the third and fourth doses (61.8% and 73.1%, respectively). Turkovac was administered only in booster doses (third dose 0.6%, fourth dose 4.8%). The adjusted relative vaccine effectiveness (rVE) was found to be 61.8% (95% confidence interval (CI) 51.5-69.9) in two doses of inactivated vaccine and one dose of mRNA vaccine schedule compared to the homolog booster of CoronaVac primary vaccine schedule. In two booster doses receipts, the adjusted rVE was found to be 45.4% (95% CI 13.8-65.4) in three doses of inactivated and one dose mRNA vaccine schedule and 43.0% (95% CI 20.5-59.2) in two doses of inactivated and two doses of mRNA vaccines schedule compared to the two homolog boosters with CoronaVac primary vaccine schedule.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In this study, the effectiveness of the mRNA vaccine as a booster dose was higher than that of the homologous boosters in participants receiving the CoronaVac primary series for those aged 65 and over.</AbstractText><CopyrightInformation>© The Author(s), 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sezerol</LastName><ForeName>Mehmet Akif</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Epidemiology Program, Institute of Health Sciences, İstanbul Medipol University, İstanbul, Türkiye.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health, School of Medicine, İstanbul Medipol University, İstanbul, Türkiye.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministry of Health, Sultanbeyli District Health Directorate, İstanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarisaltik</LastName><ForeName>Alican</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7317-404X</Identifier><AffiliationInfo><Affiliation>Department of Public Health, School of Medicine, Marmara University, Başıbüyük Mah, Maltepe Başıbüyük Yolu Sok, No. 9/2, İstanbul 34854, Türkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Vaccines Immunother</MedlineTA><NlmUniqueID>101718382</NlmUniqueID><ISSNLinking>2515-1355</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">booster</Keyword><Keyword MajorTopicYN="N">elderly</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">vaccine effectiveness</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39372967</ArticleId><ArticleId IdType="pmc">PMC11452850</ArticleId><ArticleId IdType="doi">10.1177/25151355241285375</ArticleId><ArticleId IdType="pii">10.1177_25151355241285375</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Checcucci E, Piramide F, Pecoraro A, et al.. The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans. Panminerva Med 2022; 64: 72–79.</Citation><ArticleIdList><ArticleId IdType="pubmed">32456404</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma O, Sultan AA, Ding H, et al.. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol 2020; 11: 585354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7591699</ArticleId><ArticleId IdType="pubmed">33163000</ArticleId></ArticleIdList></Reference><Reference><Citation>
Republic of Turkey Ministry of Health. COVID-19 vaccination information platform, https://covid19asi.saglik.gov.tr (2021, accessed 2 September 2023).</Citation></Reference><Reference><Citation>Gao Q, Bao L, Mao H, et al.. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020; 369: 77–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202686</ArticleId><ArticleId IdType="pubmed">32376603</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JW, Lagniton PNP, Liu Y, et al.. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci 2021; 17: 1446–1460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8071766</ArticleId><ArticleId IdType="pubmed">33907508</ArticleId></ArticleIdList></Reference><Reference><Citation>
Republic of Turkey Ministry of Health. Minister Koca announced TURKOVAC’s emergency use authorization, https://www.saglik.gov.tr (2022, accessed 1 September 2023).</Citation></Reference><Reference><Citation>Abul Y, Leeder C, Gravenstein S. Epidemiology and clinical presentation of COVID-19 in older adults. Infect Dis Clin North Am 2023; 37: 1–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9633621</ArticleId><ArticleId IdType="pubmed">36805007</ArticleId></ArticleIdList></Reference><Reference><Citation>Medetalibeyoglu A, Senkal N, Kose M, et al.. Older adults hospitalized with Covid-19: clinical characteristics and early outcomes from a Single Center in Istanbul, Turkey. J Nutr Health Aging 2020; 24: 928–937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7597420</ArticleId><ArticleId IdType="pubmed">33155617</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavuz M, Sezerol MA. The vaccination characteristics and mortal causes analysis of COVID-19 deaths at a district level. J Med Palliat Care 2023; 4: 145–150.</Citation></Reference><Reference><Citation>
Republic of Turkey Ministry of Industry and Technology. Socio-economic development ranking of districts, https://www.sanayi.gov.tr/merkez-birimi/b94224510b7b/sege (2022, accessed 5 November 2023).</Citation></Reference><Reference><Citation>
Turkish Statistical Institute. Address based population registration system, https://biruni.tuik.gov.tr/medas/?kn=95&amp;locale=tr (2023, accessed 31 October 2023).</Citation></Reference><Reference><Citation>Çağlayan D, Süner AF, Şiyve N, et al.. An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey. J Med Virol 2022; 94: 2212–2221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015267</ArticleId><ArticleId IdType="pubmed">35075655</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Ma Y, Liu Q, et al.. Comparison of the effectiveness and safety of heterologous booster doses with homologous booster doses for SARS-CoV-2 vaccines: a systematic review and meta-analysis. Int J Environ Res Public Health 2022; 19: 10752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9517782</ArticleId><ArticleId IdType="pubmed">36078466</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara A, Undurraga EA, Zubizarreta JR, et al.. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health 2022; 10: e798–e806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034854</ArticleId><ArticleId IdType="pubmed">35472300</ArticleId></ArticleIdList></Reference><Reference><Citation>Low EV, Tok PSK, Husin M, et al.. Assessment of heterologous and homologous boosting with inactivated COVID-19 vaccine at 3 months compared with homologous boosting of BNT162b2 at 6 months. JAMA Netw Open 2022; 5: e2226046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9366545</ArticleId><ArticleId IdType="pubmed">35947381</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan EYF, Mok AHY, Yan VKC, et al.. Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study. J Travel Med 2022; 29: taac119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9619717</ArticleId><ArticleId IdType="pubmed">36250571</ArticleId></ArticleIdList></Reference><Reference><Citation>Çulpan HC, Aydın SN, Uygur A, et al.. Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers. Hum Vaccin Immunother 2023; 19: 2275445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10653742</ArticleId><ArticleId IdType="pubmed">37964650</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzun O, Akpolat T, Varol A, et al.. COVID-19: vaccination vs.hospitalization. Infection 2022; 50: 747–752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8725959</ArticleId><ArticleId IdType="pubmed">34984646</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan SA, Chung H, Brown KA, et al.. Estimated effectiveness of COVID-19 vaccines against omicron or delta symptomatic infection and severe outcomes. JAMA Netw Open 2022; 5: e2232760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9500552</ArticleId><ArticleId IdType="pubmed">36136332</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowe J, Andrews N, Kirsebom F, et al.. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. Nat Commun 2022; 13: 5736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9523190</ArticleId><ArticleId IdType="pubmed">36180428</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen H, Tessier E, Turner C, et al.. Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England. Epidemiol Infect 2023; 151: e58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10125873</ArticleId><ArticleId IdType="pubmed">36938806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Yao Y, Wang Y, et al.. Determinants of COVID-19 vaccination status and hesitancy among older adults in China. Nat Med 2023; 29: 623–631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10285745</ArticleId><ArticleId IdType="pubmed">36720270</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mayo Clinic. US COVID-19 vaccine tracker: see your state’s progress, https://www.mayoclinic.org/coronavirus-covid-19/vaccine-tracker (2022, accessed 1 November 2023).</Citation></Reference><Reference><Citation>
UK Health Security Agency. National flu and COVID-19 surveillance reports: 2021 to 2022 season, https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2021-to-2022-season (2022, accessed 1 November 2023).</Citation></Reference><Reference><Citation>Sezerol MA, Davun S. COVID-19 vaccine booster dose acceptance among older adults. Vaccines 2023; 11: 542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10056148</ArticleId><ArticleId IdType="pubmed">36992126</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong AKS, Prasetyo YT, Lagura FC, et al.. Young adult preference analysis on the attributes of COVID-19 vaccine in the Philippines: a conjoint analysis approach. Public Health Pract (Oxf) 2022; 4: 100300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9293378</ArticleId><ArticleId IdType="pubmed">35874794</ArticleId></ArticleIdList></Reference><Reference><Citation>Evren H, Ünal Evren E, Argun Barış S, et al.. Comparison of adverse effects of COVID-19 vaccines among elderly: Pfizer/BioNTech Versus CoronaVac. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 2023; 14: 353–359.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>